araag2/HINT huggingface dataset:
Clinical trial NCT02655198 (phase 2, status: active, not recruiting)
Conditions: epilepsy, lennox gastaut syndrome
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801, G40.813, G40.814, G40.811, G40.812
Drugs: fenfluramine
SMILES: CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
Eligibility criteria:

        Inclusion criteria

        Electro-clinical epilepsy syndrome compatible with Lennox Gastaut syndrome:

          -  Minimum requirements (based on ILAE epilepsydiagnosis.org):

               -  Multiple seizure types including in any case tonic seizures

               -  EEG shows slow spike waves and abnormal background

               -  Abnormal cognitive development

               -  MRI compatible with Lennox Gastaut epilepsy : no progressive disease

          -  Drug resistant:

               -  at least 4 documented seizures in the last 4 weeks before inclusion (minimum 4
                  seizures in at least 2 separate weeks) Seizure types eligible for inclusion are :
                  generalized tonic-clonic seizures GTC , tonic seizures TS , atonic seizures AS or
                  clearly recognizable focal seizures FS.

               -  on >= 2 AEDs (including VNS) during the 4 weeks before inclusion (no changes in
                  treatment before inclusion and during the trial)

          -  Age between 3 and 18 years

          -  Subject is male or non-pregnant, non-lactating female. Female subjects of childbearing
             potential must not be pregnant or breast-feeding. Female subjects of childbearing
             potential must have a negative urine pregnancy test. Subjects of childbearing or
             child-fathering potential must be willing to use medically acceptable forms of birth
             control, which includes abstinence, while being treated on this study and for 90 days
             after the last dose of study drug.

        Exclusion Criteria

          -  Known clinical cardiovascular abnormalities (including valvular problems, shunts,
             pulmonary hypertension, exercise intolerance)

          -  Any cardiac ultrasound/ECG abnormalities at baseline

          -  Weight below percentile 3 for age at baseline

          -  Subject is receiving concomitant therapy with: centrally-acting anorectic agents;
             monoamine oxidase inhibitors; any centrally-acting compound with clinically
             appreciable amount of serotonin agonist or antagonist properties, including serotonin
             reuptake inhibition; atomoxetine, or other centrally-acting noradrenergic agonist;
             cyproheptadine, and/or cytochrome P450 (CYP) 2D6/3A4/2B6 inhibitors/substrates.

          -  Subject is unwilling to refrain from large or daily servings of grapefruits and/or
             Seville oranges, and their juices beginning with the Baseline Period and throughout
             the study.
Clinical trial NCT02656615 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: abiraterone acetate
SMILES: [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Reason stopped: 
    lack of patient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Written prostate cancer.

          2. Adult patients with histological or cytological diagnosis of adenocarcinoma of the
             prostate.

          3. Men with castration-resistant metastatic decline maintained for at least 3 weeks as
             per PCWG2 criteria).

          4. Confirmed biochemical response to prior abiraterone acetate (≥50% PSA Informed Consent
             (including consent for biomarker studies including the fresh tumour biopsies)

          5. Progressive disease according to PCWG2 criteria during prior therapy with standard
             dose of abiraterone acetate (confirmed increase of PSA ≥25% over nadir) or soft-tissue
             or bone progression. Patients that have stopped abiraterone acetate for reasons other
             than progression are not eligible.

          6. Documented progression of disease by any of the criteria listed here:

               -  PSA

               -  Soft tissue

               -  Bone scan all as per PCWG2 criteria

          7. Patients may have received treatment with docetaxel, enzalutamide or radium-223

          8. PSA of ≥10ug/l

          9. ECOG performance status 0 - 2

         10. At least 3 months (90 days) since stop of prior abiraterone acetate.

        Exclusion Criteria:

          1. Major surgery within 28 days weeks prior to start of treatment

          2. Prior treatment with cabazitaxel or the CYP-17 inhibitor TAK-700/orteronel

          3. Any concurrent treatment or prior treatment with an investigational drug within 28
             days prior to start of treatment.

          4. Known brain or leptomeningeal disease

          5. Concurrent use of steroids other than prednisone >10mg/d

          6. Inadequate bone marrow and organ function as evidenced by:

             Platelet count <75 x 10 G/L ASAT and/or ALAT ≥ 2.5 x ULN Total bilirubin ≥ 1.5 x ULN
             (≥ 2.0 x ULN for patients with Gilbert's disease) Hypokalaemia despite adequate
             supplementation Creatinine Clearance <30ml/min

          7. Uncontrolled hypertension or cardiac failure or LVEF <50%

        creatinine clearance is to be calculated by using the formula of Cockcroft-Gault in
        appendix 4 of the protocol
Clinical trial NCT02657915 (phase 2, status: completed)
Conditions: acute optic neuritis
ICD codes: A17.83, A39.82, H46.13, H46.8, H46.9, H46.10, H46.11
Drugs: placebo, biib033 100mg/kg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Must have participated in Study NCT01721161 and received at least 1 dose of BIIB033 or
             placebo, as per protocol, within 2 years (+ 4 months) from Day 1 of this study (2
             years from Week 32 or projected Week 32 visit, if the subject did not complete all
             visits in Study NCT01721161).

        Key Exclusion Criteria:

          -  Not previously enrolled in Study NCT01721161

          -  Subjects with recent kidney function, such as serum creatinine above upper limit of
             normal range, will not be allowed to receive administration of Gd but will otherwise
             be allowed to participate in the study, including magnetic resonance imaging (MRI)
             assessments not requiring the use of Gd.

          -  Female subjects must have had a recent pregnancy test and must not be breastfeeding
             prior to MRI assessments with Gd.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02658344 (phase 2, status: completed)
Conditions: degenerative arthritis, knee osteoarthritis
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: saline solution
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18 and older, male and female

          2. Patients must consent in writing to participate in the study by signing and dating an
             informed consent document

          3. Diagnosis of osteoarthritis by ACR osteoarthritis of the knee

          4. Diagnosis of osteoarthritis by radiographic criteria of Kellgren and Lawrence grade
             2-4

          5. More than Grade 4 (0~10 point numeric scale) pain at least for 12 weeks

          6. Diagnosis of osteoarthritis of class Ⅰ~Ⅲ by ACR(American College of Rheumatology
             Criteria) Global functional criteria

          7. Patient who agree with contraception

        Exclusion Criteria:

          1. Preparing for Pregnancy or Pregnant women or lactating mothers.

          2. Patients with Body Mass Index (BMI) > 35.

          3. Patients with other disease including

             : Septic arthritis, Rheumatoid or Inflammatory joint disease, Crystalline disease
             (gout or pseudogout), Paget disease, Articular fractures, Ochronosis, Acromegaly,
             Hemochromatosis, Wilson's disease, Osteochondromatosis, Hereditary disorder

          4. Patients with serious condition internal medicine disease

          5. Patients with positive human immunodeficiency (HIV), hepatitis B (HBV), hepatitis C
             (HCV), syphilis at screening indicative of current of pass infection.

          6. Patient with behavioral disorders, cognitive disorders and chronic mental symptoms

          7. Patient with significant neurologic or psychiatric disorders

          8. Patients who alcohol, drug abuse history

          9. Patients who had participated in other clinical trials within 12 weeks prior to this
             study.

         10. Patients who received any drug by intra-articular injection for treatment within 2
             months prior to this enrollment.

         11. Patients who experienced as the knee joint cartilage and stem cell therapy

         12. Patients who the principal investigator considers inappropriate for the clinical trial
             due to any other reasons than those listed above

         13. Patients who penicillin hypersensitivity reactions -
Clinical trial NCT02658357 (phase 2, status: completed)
Conditions: schizophrenia, schizo-affective disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: risperidone implant
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          1. Subject (and/or a subject's authorized legal representative) has provided written
             informed consent

          2. Patient meets the following criteria:

               -  Outpatient status

               -  PANSS Total Score ≤ 80 at screening and if PANSS score at baseline is ≥ 20%
                  change from screening, the patients cannot participate in the study.

               -  A score of ≤ 3 on the following PANSS items:

                    -  Conceptual disorganization

                    -  Suspiciousness

                    -  Hallucinatory behavior

                    -  Unusual thought content

          3. Subject is male or female between 18 to 60 years of age

          4. Subject has a diagnosis of schizophrenia or schizoaffective disorder according to
             Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria

        Exclusion Criteria:

          1. Hospitalized or required acute crisis intervention for symptom exacerbation in the 60
             days prior to admission as determined by the Investigator

          2. Subject has a history of suicide attempt in the last year, or in the opinion of the
             investigator is currently at imminent risk of suicide

          3. Has a current or recent (within 12 months) DSM-V diagnosis of moderate or severe
             substance use disorder (except for tobacco use disorder) or has a positive urine drug
             screen for prohibited substances at screening.

          4. Have impaired hepatic (ALT/AST >1.5 times higher than the upper limit of normal) or
             renal function (eGFR<50 mL/min)

          5. Previously defined hypersensitivity to Risperidone

          6. History of neuromalignant syndrome (NMS)

          7. Electroconvulsive therapy within 6 months of admission

          8. Requires current use of agents that are strong inhibitors and inducers of cytochrome
             P450 2D6
Clinical trial NCT02659397 (phase 2, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: etc-1002, atorvastatin, placebo
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Taking daily stable statin doses for at least 4 weeks prior to screening visit.

          -  LDL-C between 100-220 mg/dL for patients taking daily high-intensity statin (for 4
             weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all
             other lipid-regulating drugs and supplements) at the screening visit; or,

          -  LDL-C between 115-220 mg/dL for patients taking moderate- or low-intensity statin (for
             4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping
             all other lipid-regulating drugs and supplements) at the screening visit.

          -  Must be willing to discontinue other lipid-regulating therapies during the study

        Exclusion Criteria:

          -  History of acute significant cardiovascular disease.

          -  Current clinically significant cardiovascular disease.

          -  History of inability to tolerate any statin at any dose due to muscle-related pain or
             weakness.
Clinical trial NCT02669433 (phase 2, status: completed)
Conditions: dementia with lewy bodies
ICD codes: G31.83
Drugs: rvt-101 35 mg, rvt-101 70 mg, placebo
SMILES: O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subject with probable DLB

          -  Mini Mental State Examination (MMSE) score of 14-26 inclusive at Screening and
             Baseline

          -  Patient has the ability to comply with procedures for cognitive and other testing in
             the opinion of the investigator

          -  Patient has a reliable caregiver who is willing to report on the subject's status
             throughout the study

          -  Patients currently receiving therapy for DLB are eligible for enrollment

        Exclusion Criteria:

          -  Atypical clinical features or clinical course that would lead the investigator to
             conclude primary symptoms are more likely explained by an alternate dementia
             diagnosis.

          -  Any clinically relevant concomitant disease that, in the opinion of the investigator,
             makes the patient unsuitable for inclusion in the study.
Clinical trial NCT02679079 (phase 2, status: completed)
Conditions: tourette syndrome
ICD codes: F95.2
Drugs: nbi-98854, placebo
SMILES: COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Have a clinical diagnosis of Tourette Syndrome (TS)

          2. Have at least moderate tic severity

          3. Have TS symptoms that impair school, occupational, and/or social function

          4. If using maintenance medication(s) for TS or TS spectrum diagnoses (e.g.
             obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]),
             be on stable doses

          5. Be in good general health

          6. Adolescent subjects (12 to 17 years of age) must have a negative urine drug screen for
             amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or
             cannabinoids and a negative alcohol screen

          7. Subjects of childbearing potential who do not practice total abstinence must agree to
             use hormonal or two forms of nonhormonal contraception (dual contraception)
             consistently during the screening, treatment and follow-up periods of the study

        Exclusion Criteria:

          1. Have an active, clinically significant unstable medical condition within 1 month prior
             to screening

          2. Have a known history of long QT syndrome or cardiac arrhythmia

          3. Have a known history of neuroleptic malignant syndrome

          4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)

          5. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors

          6. Have a blood loss ≥250 mL or donated blood within 30 days prior to screening

          7. Have a known history of substance dependence, substance (drug) or alcohol abuse

          8. Have a significant risk of suicidal or violent behavior

          9. Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the
             screening period or at baseline or plan to initiate CBIT during the study

         10. Have received an investigational drug within 30 days before screening or plan to use
             an investigational drug (other than NBI-98854) during the study
Clinical trial NCT02681809 (phase 2, status: terminated)
Conditions: diabetic retinopathy, posterior vitreous detachment, disease progression
ICD codes: H35.23, H35.20, H35.21, H35.22, E10.3553, E11.3553, E13.3553
Drugs: ocriplasmin 0.0625mg, ocriplasmin 0.125mg, sham injection
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    slow recruitment rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 years or older

          -  Best-corrected visual acuity (BCVA) of 65 letters read or greater (Snellen equivalent
             of 20/50 or better) in the study eye

          -  HbA1c ≤ 12%, as assessed by the central laboratory

          -  Moderate to very severe NPDR as per ETDRS Severity Scale, based on 7 standard field
             stereo colour fundus photograph

          -  Central subfield thickness of ≤ 340µm on Spectralis SD-OCT or ≤ 320µm on
             non-Spectralis SD OCT in the study eye, with or without mild centre-involved diabetic
             macular oedema

          -  No evidence of total PVD in the study eye

          -  Written informed consent obtained from the subject prior to screening procedures

        Exclusion Criteria:

          -  History of or current ocular condition in the study eye that may interfere with the
             assessment of the progression to PDR

          -  Presence of epiretinal membrane in the study eye

          -  Presence of foveal ischemia in the study eye

          -  Presence of pre-retinal or vitreous haemorrhage in the study eye

          -  Presence of iris or angle neovascularisation in the study eye

          -  Any active ocular / intraocular infection or inflammation in either eye

          -  Aphakic study eye

          -  Uncontrolled hypertension in the opinion of the Investigator

          -  Pseudoexfoliation, Marfan's syndrome, phacodonesis or any other finding in the
             Investigator's opinion suggesting lens / zonular instability
Clinical trial NCT02683161 (phase 2, status: terminated)
Conditions: cigarette smoking, obesity
ICD codes: X08.01XS, X08.11XS, X08.01XA, X08.01XD, X08.11XA, X08.11XD, X08.21XS, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: varenicline
SMILES: [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21
Reason stopped: 
    inability to adequately recruit participants during pre-post operative period.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Smoker who has surgery scheduled 5-10 weeks in advance

        Exclusion Criteria:

          -  being contraindicated for varenicline use

          -  evidence of psychiatric instability

          -  being unwilling/unable to adhere to the study schedule

          -  be unwilling to provide study access to medical records

          -  being otherwise judged by the study team to be inappropriate for study participation
Clinical trial NCT02685046 (phase 2, status: terminated)
Conditions: colonic neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: imatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Reason stopped: 
    low accrual rate
  
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female aged ≥18 years

          2. Histologically proven adenocarcinoma of the colon;

          3. Completed cancer staging with CT-abdomen and CT-thorax/X-thorax according to
             hospital's standard of care;

          4. Confirmed eligibility for surgery with curative intent as deemed by the hospital's
             multidisciplinary board (MDB) review;

          5. An intratumoural gene expression profile of PDGFR-α, PDGFR-β, PDGF-C and KIT,
             indicative of the mesenchymal phenotype, according to our diagnostic RT-qPCR test
             (i.e. more than 50% chance of having the mesenchymal phenotype);

          6. Minimum of four properly stored pre-treatment biopsies for gene expression
             analysis/ELISA;

          7. WHO performance status 0 or 1;

          8. Adequate haematology status and organ function, defined as:

               -  Normal creatinine clearance (≥60 ml/min (MRDR))

               -  ALAT within 2.5x upper limit of normal (ULN)

               -  PT-INR < 1.5

               -  Leukocytes > 1,5*10^9/L; Hb > 6.0 mmol/L; platelets > 100*10^9/L

          9. Willingness and ability to comply with scheduled visits, treatment plans and
             laboratory tests;

         10. Written informed consent.

        Exclusion Criteria:

          1. The presence of synchronous distant metastases;

          2. Current hospital standard of care dictates that subject should undergo any neoadjuvant
             therapy;

          3. Concurrent participation in another clinical trial using any medicinal product, or
             participation in such a trial in the period of three months prior to the current
             trial;

          4. Women who are pregnant, plan to become pregnant or are lactating during the study or
             for up to 30 days after the last dose of imatinib;

          5. Known HIV or Hepatitis B/C infection;

          6. Known symptomatic congestive heart failure;

          7. Co-morbidity requiring concomitant treatment with drugs that act as strong inducers of
             CYP3A4 or with drugs with a narrow therapeutic range influenced by imatinib
Clinical trial NCT02685345 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ds-8500a 25 mg, ds-8500a 75 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese patients with type 2 diabetes

          -  Patients aged ≥ 20 years at the time of informed consent

          -  Patients who have been treated with sitagliptin 50 mg monotherapy for the treatment of
             type 2 diabetes mellitus

          -  Patients who have HbA1c ≥ 7.0% and < 9.0%

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or
             ketoacidosis

          -  Patients receiving or requiring treatment with insulin

          -  Patients with a body mass index (BMI) of < 18.5 kg/m2 or ≥ 35.0 kg/m2

          -  Patients with clinically evident renal impairment (estimated glomerular filtration
             rate [eGFR] of < 45 mL/min per 1.73 m2) or clinically significant renal disease

          -  Patients with fasting plasma glucose ≥ 240 mg/dL